Medicamen Biotech Ltd. (MEDICAM) Share Price Rises 9.30% Today
- August 28, 2026
- Posted by: Harsh Piplani
- Category: News
Medicamen Biotech Ltd. Share Price moved higher today as the stock rose 9.30% to Rs 250.95 from Rs 229.60, with market capitalisation at Rs 325.91 Cr. The day’s range stretched from Rs 221.70 to Rs 250.95, while turnover stood at Rs 0.06 Cr. This Medicamen Biotech Ltd. Share Price move confirms a clear same-day gain, but the supplied data does not establish a company-specific catalyst. For readers tracking Medicamen Biotech Ltd. Stock News, the important context is that the move came in the Healthcare sector, within the Pharmaceuticals & Drugs industry, against a backdrop of valuation and profitability metrics that can be assessed directly. Univest is covering the event as a factual price rise, not as a forecast. Investors following Medicamen Biotech Ltd. Share Price Today can monitor how the stock behaves around Rs 250.95 and how today’s move fits with the company’s financial profile.
Medicamen Biotech Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 250.95 |
| Previous Close | Rs 229.6 |
| Today's Move | Rs 21.35 (+9.3%) |
| Open | Rs 225.05 |
| High | Rs 250.95 |
| Low | Rs 221.7 |
| Turnover | Rs 0.06 crore |
| Market Capitalisation | Rs 325.91 crore |
| Market Cap Category | Micro Cap |
Medicamen Biotech Ltd. (MEDICAM) rose to Rs 250.95 from the previous close of Rs 229.6, a move of Rs 21.35 or 9.3%. The stock opened at Rs 225.05, reached a high of Rs 250.95, recorded a low of Rs 221.7.
Medicamen Biotech Ltd. Share Price today closed at Rs 250.95, up Rs 21.35 or 9.30% from the previous close of Rs 229.60. The stock opened at Rs 225.05, moved within a day range of Rs 221.70 to Rs 250.95, and finished at the day’s high. That makes the move an event-led price rise rather than a broad narrative call. In Medicamen Biotech Ltd. Stock News terms, the verified facts are straightforward: the share price update was positive, the stock was among the day’s notable risers, and turnover was Rs 0.06 Cr. Univest notes the event as a same-day share price gain, while the data itself does not identify a separate trigger.
Medicamen Biotech Ltd. (MEDICAM) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 325.91 crore |
| P/E Ratio | 28.76x |
| P/B Ratio | 1.15x |
| ROE | 3.23% |
| ROCE | 5.77% |
| EPS | Rs 7.98 |
| Book Value Per Share | Rs 199.52 |
| Dividend Yield | 0.44% |
Medicamen Biotech Ltd. (MEDICAM) fundamental metrics show P/E 28.76x, P/B 1.15x, ROE 3.23%, ROCE 5.77%. These figures provide context only and are not a buy or sell signal.
Medicamen Biotech Ltd. has a market capitalisation of Rs 325.91 crore and falls in the Micro Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 28.76x, P/B at 1.15x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 3.23% and ROCE of 5.77%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 7.98, book value per share of Rs 199.52, dividend yield of 0.44%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.16x, median ROE of 11.82%, median ROCE of 13.71%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 28.76x |
| Benchmark Median P/E | 31.16x |
| Benchmark Average P/E | 48.05x |
| Benchmark P/E Range | 3.36x to 397.25x |
| Company P/B Ratio | 1.15x |
| Benchmark Median P/B | 2.71x |
| Company ROE | 3.23% |
| Benchmark Median ROE | 11.82% |
| Company ROCE | 5.77% |
| Benchmark Median ROCE | 13.71% |
| Company Market Capitalisation | Rs 325.91 crore |
| Benchmark Median Market Cap | Rs 664.09 crore |
Medicamen Biotech Ltd. (MEDICAM) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 28.76x, which is below the benchmark median of 31.16x, a difference of -7.7%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Medicamen Biotech Ltd. (MEDICAM) has a ROE of 3.23%, which is below the benchmark median of 11.82%, a difference of -72.67%. Medicamen Biotech Ltd. (MEDICAM) has a ROCE of 5.77%, which is below the benchmark median of 13.71%, a difference of -57.91%.
Track stocks leading today through the Univest top gainers screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | SUNPHARMA | 4,56,113.58 | 37.7 | 5.27 | 14.85 | 19.11 |
| Divi's Laboratories Ltd. | DIVISLAB | 2,39,321.25 | 82.14 | 13.6 | 16.19 | 21.51 |
| Torrent Pharmaceuticals Ltd. | TORNTPHARM | 1,85,923.81 | 87.64 | 21.3 | 26.76 | 19.27 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,14,508.45 | 26.28 | 4.4 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,13,778.04 | 34.03 | 3.26 | 11.83 | 16 |
Medicamen Biotech Ltd. (MEDICAM) has a P/E ratio of 28.76x compared with the displayed peer median of 37.7x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 3.23% compares with a peer median of 16.19% across the companies shown in the table. ROCE stood at 5.77% versus the displayed peer median of 19.27%, providing a capital-efficiency comparison. Medicamen Biotech Ltd. (MEDICAM) has a market capitalisation of Rs 325.91 crore. Among the 5 peers shown, 5 have a larger market capitalisation.
Why Investors Are Watching Medicamen Biotech Ltd.
- Medicamen Biotech Ltd. Share Price rose 9.30% today to Rs 250.95.
- The stock closed at the day’s high of Rs 250.95 after opening at Rs 225.05.
- Market capitalisation stands at Rs 325.91 Cr, with P/E at 28.76 and P/B at 1.15.
- ROE is 3.23% and ROCE is 5.77%, which are below the supplied industry medians.
- Within the peer set, the Medicamen Biotech Ltd. Share Price sits on a lower valuation and smaller market cap base than most comparables.
About Medicamen Biotech Ltd.
Medicamen Biotech Ltd. is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. The supplied dataset does not provide a detailed segment breakup, so the clearest company view comes from its market classification and financial profile. Medicamen Biotech Ltd. Share Price today reflects a listed pharmaceutical business with a market cap of Rs 325.91 Cr, a P/E of 28.76, a P/B of 1.15, EPS of Rs 7.98 and book value of Rs 199.52 per share. The dividend yield is 0.44%, which adds a small income component to the stock’s profile. For readers using Medicamen Biotech Ltd. Stock News and Medicamen Biotech Ltd. Share News searches, the available company data supports a valuation-led review rather than a narrative built on operating detail. Univest keeps the focus on verified numbers only.
Track Medicamen Biotech Ltd. Share Price on Univest
Use Medicamen Biotech Ltd. (MEDICAM) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top-gainers lists and related market analysis.
You can track Medicamen Biotech Ltd. Share Price on Univest for live share price updates, valuation ratios, shareholding pattern, 52-week levels and broader market insights. Univest also helps users review Medicamen Biotech Ltd. Stock Analysis, Medicamen Biotech Ltd. Fundamental Analysis and Medicamen Biotech Ltd. Share Price Live in one place. For investors monitoring Medicamen Biotech Ltd. Latest News, the platform brings the same verified market data into a single view. Univest is designed to make Medicamen Biotech Ltd. Share Price Today easier to follow without relying on assumptions or unsupported commentary.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why did Medicamen Biotech Ltd. share price rise today?
Ans. Medicamen Biotech Ltd. Share Price rose 9.30% to Rs 250.95, but the supplied data does not establish a company-specific catalyst. The event is verified as a same-day price rise, with turnover at Rs 0.06 Cr.
What is Medicamen Biotech Ltd. share price today?
Ans. Medicamen Biotech Ltd. Share Price Today is Rs 250.95. It was up Rs 21.35 from the previous close of Rs 229.60, and the stock finished at the day’s high after moving between Rs 221.70 and Rs 250.95.
How much did Medicamen Biotech Ltd. stock gain today?
Ans. Medicamen Biotech Ltd. Stock Gaining Today means the share price increased by 9.30%, or Rs 21.35, in a single session. The move took the stock from Rs 229.60 to Rs 250.95.
What is Medicamen Biotech Ltd. market cap?
Ans. Medicamen Biotech Ltd. Market Cap is Rs 325.91 Cr. That places the company below the same-industry benchmark median of Rs 664.09 Cr, based on the supplied healthcare and pharmaceuticals dataset.
What is Medicamen Biotech Ltd. valuation on P/E and P/B?
Ans. Medicamen Biotech Ltd. Share Price sits alongside a P/E of 28.76 and a P/B of 1.15. In the supplied industry set, the P/E is below the median, while the P/B is also below the median.
How do Medicamen Biotech Ltd. fundamentals look?
Ans. Medicamen Biotech Ltd. Fundamental Analysis shows EPS of Rs 7.98, book value of Rs 199.52, ROE of 3.23%, ROCE of 5.77% and dividend yield of 0.44%. These figures provide context for the day’s price rise.
How does Medicamen Biotech Ltd. compare with healthcare peers?
Ans. Compared with peers like Sun Pharma, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, Medicamen Biotech Ltd. has a much smaller market cap and lower P/B. Its P/E is also lower than most listed comparables.
